Cree antidiabetic plant extracts display mechanism-based inactivation of CYP3A4

Canadian Journal of Physiology and Pharmacology

Volumn 89, Issue 1, 2011, Pages 13-23

  Tam, Teresa W ^a   Liu, Rui ^a   Arnason, John T ^a   Krantis, Anthony ^a   Staines, William A ^a   Haddad, Pierre S ^b   Foster, Brian C ^a,c  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c HEALTH CANADA   (Canada)

Author keywords

Aboriginal; Cree; CYP3A4; Diabetes mellitus; Dibenzylfluorescein; Mechanism based inactivation; Natural products; Testosterone; Traditional medicine

Indexed keywords

ABIES BALSAMEA EXTRACT; ALNUS INCANA EXTRACT; CREE EXTRACT; CYTOCHROME P450 3A4; DIBENZYLFLUORESCEIN; FLUORESCEIN DERIVATIVE; KALMIA ANGUSTIFOLIA EXTRACT; LYCOPODIUM CLAVATUM EXTRACT; PICEA GLAUCA EXTRACT; PICEA MARIANA EXTRACT; PINUS BANKSIANA EXTRACT; PLANT EXTRACT; PLANT MEDICINAL PRODUCT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; RHODODENDRON TOMENTOSUM EXTRACT; SARRACENIA PURPUREA EXTRACT; TESTOSTERONE; UNCLASSIFIED DRUG;

ABIES BALSAMEA; ALNUS INCANA; ARTICLE; BINDING AFFINITY; BLACK SPRUCE; CONTROLLED STUDY; DRUG INHIBITION; DRUG POTENCY; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME METABOLISM; ENZYME SUBSTRATE; FLUOROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; KALMIA ANGUSTIFOLIA; LYCOPODIUM; MEDICINAL PLANT; MICROTITER FLUOROMETRIC ASSAY; NONHUMAN; PINUS BANKSIANA; PRIORITY JOURNAL; RHODODENDRON TOMENTOSUM; SARRACENIA PURPUREA; WHITE SPRUCE;

COMPLEMENTARY THERAPIES; CYTOCHROME P-450 CYP3A; DIABETES MELLITUS, TYPE 2; HORTICULTURAL THERAPY; HUMANS; HYDRASTIS; HYPOGLYCEMIC AGENTS; INDIANS, NORTH AMERICAN; PLANT EXTRACTS; PLANTS, MEDICINAL; QUEBEC; SUBSTRATE SPECIFICITY;

EID: 78650529149     PISSN: 00084212     EISSN: 12057541     Source Type: Journal    
DOI: 10.1139/Y10-104     Document Type: Article

References (52)

1. Bano, G., Amla, V., Raina, R.K., Zutshi, U., and Chopra, C.L. 1987. The effect of piperine on pharmacokinetics of phenytoin in healthy volunteers. Planta Med. 53(6): 568-569. doi:10.1055/ s-2006-962814. PMID:3444866.
2. Bhardwaj, R.K., Glaeser, H., Becquemont, L., Klotz, U., Gupta, S.K., and Fromm, M.F. 2002. Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4. J. Pharmacol. Exp. Ther. 302(2): 645-650. doi:10.1124/jpet.102. 034728. PMID:12130727.
3. Busfield, F., Duffy, D.L., Kesting, J.B., Walker, S.M., Lovelock, P.K., Good, D., et al. 2002. A genomewide search for type 2 diabetes-susceptibility genes in indigenous Australians. Am. J. Hum. Genet. 70(2): 349-357. doi:10.1086/338626. PMID: 11742441.
4. Chan, W.K., and Delucchi, A.B. 2000. Resveratrol, a red wine constituent, is a mechanism-based inactivator of cytochrome P450 3A4. Life Sci. 67(25): 3103-3112. doi:10.1016/S0024-3205(00) 00888-2. PMID:11125847.
5. Chang, T.K.H., and Yeung, R.K.Y. 2001. Effect of trans-resveratrol on 7-benzyloxy-4-trifluoromethylcoumarin O-dealkylation catalyzed by human recombinant CYP3A4 and CYP3A5. Can. J. Physiol. Pharmacol. 79(3): 220-226. doi:10.1139/cjpp-79-3-220. PMID:11294598.
6. Chatterjee, P., and Franklin, M.R. 2003. Human cytochrome P450 inhibition and metabolic-intermediate complex formation by goldenseal extract and its methylenedioxyphenyl components. Drug Metab. Dispos. 31(11): 1391-1397. doi:10.1124/dmd.31. 11.1391. PMID:14570772.
7. Chen, Y., Liu, W.H., Chen, B.L., Fan, L., Han, Y., Wang, G., et al. 2010. Plant polyphenol curcumin significantly affects CYP1A2 and CYP2A6 activity in healthy, male Chinese volunteers. Ann. Pharmacother. 44(6): 1038-1045. doi:10.1345/aph.1M533. PMID:20484172.
8. Cohen, P.A., and Ernst, E. 2010. Safety of herbal supplements: a guide for cardiologists. Cardiovasc Ther, 28(4): 246-253. doi:10.1111/j.1755-5922.2010.00193.x. PMID:20633025.
9. Colalto, C. 2010. Herbal interactions on absorption of drugs: mechanisms of action and clinical risk assessment. Pharmacol. Res. 62(3): 207-227. doi:10.1016/j.phrs.2010.04.001. PMID: 20399862.
10. Dufour, D., Pichette, A., Mshvildadze, V., Bradette-Hébert, M.E., Lavoie, S., Longtin, A., et al. 2007. Antioxidant, anti-inflammatory and anticancer activities of methanolic extracts from Ledum groenlandicum Retzius. J. Ethnopharmacol. 111(1): 22-28. doi:10.1016/j.jep.2006.10.021. PMID:17156957.
11. Eid, H.M., Martineau, L.C., Saleem, A., Muhammad, A., Vallerand, D., Benhaddou-Andaloussi, A., et al. 2010. Stimulation of AMP-activated protein kinase and enhancement of basal glucose uptake in muscle cells by quercetin and quercetin glycosides, active principles of the antidiabetic medicinal plant Vaccinium vitis-idaea. Mol. Nutr. Food Res. 54(7): 991-1003. doi:10. 1002/mnfr.200900218. PMID:20087853.
12. Flanagan, D. 2005. Understanding the grapefruit-drug interaction. Gen. Dent. 53(4): 282-285 quiz 286. PMID:16158798.
13. Fontana, E., Dansette, P.M., and Poli, S.M. 2005. Cytochrome P450 enzymes mechanism based inhibitors: common sub-structures and reactivity. Curr. Drug Metab. 6(5): 413-454. doi:10. 2174/138920005774330639. PMID:16248836.
14. Foster, B.C., Arnason, J.T., and Briggs, C.J. 2005. Natural health products and drug disposition. Annu. Rev. Pharmacol. Toxicol. 45(1): 203-226. doi:10.1146/annurev.pharmtox.45.120403.095950. PMID:15822175.
15. Ghahramani, P., Ellis, S.W., Lennard, M.S., Ramsay, L.E., and Tucker, G.T. 1997. Cytochromes P450 mediating the N-de-methylation of amitriptyline. Br. J. Clin. Pharmacol. 43(2): 137-144. doi:10.1046/j.1365-2125.1997.05382.x. PMID:9131945.
16. Greenblatt, D.J., von Moltke, L.L., Harmatz, J.S., Chen, G., Weemhoff, J.L., Jen, C., et al. 2003. Time course of recovery of cytochrome P450 3A function after single doses of grapefruit juice. Clin. Pharmacol. Ther. 74(2): 121-129. doi:10.1016/S0009-9236(03)00118-8. PMID:12891222.
17. Harbilas, D., Martineau, L.C., Harris, C.S., Adeyiwola-Spoor, D.C.A., Saleem, A., Lambert, J., et al. 2009. Evaluation of the antidiabetic potential of selected medicinal plant extracts from the Canadian boreal forest used to treat symptoms of diabetes: part II. Can. J. Physiol. Pharmacol. 87(6): 479-492. doi:10.1139/Y09-029. PMID:19526043.
18. Hegele, R.A., Zinman, B., Hanley, A.J.G., Harris, S.B., Barrett, P.H., and Cao, H. 2003. Genes, environment and Oji-Cree type 2 diabetes. Clin. Biochem. 36(3): 163-170. doi:10.1016/S0009-9120(03)00004-3. PMID:12726923.
19. Jiang, W., Wang, X., Xu, X., and Kong, L. 2010. Effect of Schisandra sphenanthera extract on the concentration of tacrolimus in the blood of liver transplant patients. Int. J. Clin. Pharmacol. Ther. 48(3): 224-229. PMID:20197017.
20. Kartha, J.S., and Yost, G.S. 2008. Mechanism-based inactivation of lung-selective cytochrome P450 CYP2F enzymes. Drug Metab. Dispos. 36(1): 155-162. doi:10.1124/dmd.107.017897. PMID: 17962375.
21. Kenworthy, K.E., Bloomer, J.C., Clarke, S.E., and Houston, J.B. 1999. CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. Br. J. Clin. Pharmacol. 48(5): 716-727. doi:10.1046/j.1365-2125.1999.00073.x. PMID:10594474.
22. Kroes, R., Galli, C., Munro, I., Schilter, B., Tran, L.-A., Walker, R., and Wurtzen, G. 2000. Threshold of toxicological concern for chemical substances present in the diet: a practical tool for assessing the need for toxicity testing. Food Chem. Toxicol. 38(2-3): 255-312. doi:10.1016/S0278-6915(99)00120-9. PMID: 10717364.
23. Lafite, P., Dijols, S., Zeldin, D.C., Dansette, P.M., and Mansuy, D. 2007. Selective, competitive and mechanism-based inhibitors of human cytochrome P450 2J2. Arch. Biochem. Biophys. 464(2): 155-168. doi:10.1016/j.abb.2007.03.028. PMID:17470359.
24. Leduc, C., Coonishish, J., Haddad, P., and Cuerrier, A. 2006. Plants used by the Cree Nation of Eeyou Istchee (Quebec, Canada) for the treatment of diabetes: a novel approach in quantitative ethnobotany. J. Ethnopharmacol. 105(1-2): 55-63. doi:10.1016/j. jep.2005.09.038. PMID:16297584.
25. Lilja, J.J., Kivisto, K.T., and Neuvonen, P.J. 2000. Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin. Clin. Pharmacol. Ther. 68(4): 384-390. doi:10.1067/mcp.2000.110216. PMID:11061578.
26. Lian-Qing, G., Fukuda, K., Ohta, T., and Yamazoe, Y. 2000. Role of furanocoumarin derivatives on grapefruit juice-mediated inhibition of human CYP3A activity. Drug Metab. Disposit. 28(7): 766-771.
27. Martineau, L.C., Muhammad, A., Saleem, A., Hervé, J., Harris, C.S., Arnason, J.T., and Haddad, P.S. 2010. Anti-adipogenic activities of Alnus incana and Populus balsamifera bark extracts, part II: bioassay-guided identification of actives salicortin and oregonin. Planta Med. 76(14): 1519-1524. PMID:20301058.
28. Naritomi, Y., Teramura, Y., Terashita, S., and Kagayama, A. 2004. Utility of microtiter plate assays for human cytochrome P450 in-hibition studies in drug discovery: application of simple method for detecting quasi-irreversible and irreversible inhibitors. Drug Metab. Pharmacokinet. 19(1): 55-61. doi:10.2133/dmpk.19.55. PMID:15499170.
29. Neuvonen, P.J., Niemi, M., and Backman, J.T. 2006. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin. Pharmacol. Ther. 80(6): 565-581. doi:10.1016/j. clpt.2006.09.003. PMID:17178259.
30. Piver, B., Berthou, F., Dreano, Y., and Lucas, D. 2001. Inhibition of CYP3A, CYP1A and CYP2E1 activities by resveratrol and other non volatile red wine components. Toxicol. Lett. 125(1-3): 83-91. doi:10.1016/S0378-4274(01)00418-0. PMID: 11701226.
31. Pollex, R.L., Hanley, A.J.G., Zinman, B., Harris, S.B., Khan, H.M.R., and Hegele, R.A. 2006. Metabolic syndrome in aboriginal Canadians: prevalence and genetic associations. Atherosclerosis, 184(1): 121-129. doi:10.1016/j.atherosclerosis.2005. 03.024. PMID:15869758.
32. Rogers, J.D., Zhao, J., Liu, L., Amin, R.D., Gagliano, K.D., Porras, A.G., et al. 1999. Grapefruit juice has minimal effects on plasma concentrations of lovastatin-derived 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Clin. Pharmacol. Ther. 66(4): 358-366. doi:10.1053/cp.1999.v66.a101208. PMID:10546919.
33. Ruschitzka, F., Meier, P.J., Turina, M., Luscher, T.F., and Noll, G. 2000. Acute heart transplant rejection due to Saint John's wort. Lancet, 355(9203): 548-549. doi:10.1016/S0140-6736(99) 05467-7. PMID:10683008.
34. Saleem, A., Harris, C.S., Asim, M., Cuerrier, A., Martineau, L., Haddad, P.S., and Arnason, J.T. 2010. A RP-HPLC-DAD-APCI/MSD method for the characterisation of medicinal Ericaceae used by the Eeyou Istchee Cree First Nations. Phytochem. Anal. 21(4): 328-339. doi:10.1002/pca.1203. PMID:20135709.
35. Scheen, A.J. 2007. Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide. Clin. Pharmacokinet. 46(2): 93-108. doi:10.2165/ 00003088-200746020-00001. PMID:17253883.
36. Schrag, M.L., and Wienkers, L.C. 2001. Covalent alteration of the CYP3A4 active site: evidence for multiple substrate binding domains. Arch. Biochem. Biophys. 391(1): 49-55. doi:10.1006/ abbi.2001.2401. PMID:11414684.
37. Siest, G., Jeannesson, E., and Visvikis-Siest, S. 2007. Enzymes and pharmacogenetics of cardiovascular drugs. Clin. Chim. Acta, 381(1): 26-31. doi:10.1016/j.cca.2007.02.014. PMID:17362901.
38. Spoor, D.C.A., Martineau, L.C., Leduc, C., Benhaddou-Andaloussi, A., Meddah, B., Harris, C., et al. 2006. Selected plant species from the Cree pharmacopoeia of northern Quebec possess antidiabetic potential. Can. J. Physiol. Pharmacol. 84(8-9): 847-858. doi:10.1139/Y06-018. PMID:17111029.
39. Sridar, C., Goosen, T.C., Kent, U.M., Williams, J.A., and Hollenberg, P.F. 2004. Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases. Drug Metab. Dispos. 32(6): 587-594. doi:10.1124/dmd. 32.6.587. PMID:15155549.
40. Takanaga, H., Ohnishi, A., Murakami, H., Matsuo, H., Higuchi, S., Urae, A., et al. 2000. Relationship between time after intake of grapefruit juice and the effect on pharmacokinetics and pharma-codynamics of nisoldipine in healthy subjects. Clin. Pharmacol. Ther. 67(3): 201-214. doi:10.1067/mcp.2000.104215. PMID: 10741622.
41. Tam, T.W., Liu, R., Arnason, J.T., Krantis, A., Staines, W.A., Haddad, P.S., and Foster, B.C. 2009. Actions of ethnobotanically selected Cree anti-diabetic plants on human cytochrome P450 isoforms and flavin-containing monooxygenase 3. J. Ethnopharmacol. 126(1): 119-126. doi:10.1016/j.jep.2009.07.036. PMID:19665535.
42. Triplitt, C. 2006. Drug interactions of medications commonly used in diabetes. Diabetes Spectrum, 19(4): 202-211. doi:10.2337/ diaspect.19.4.202.
43. Williams, D., and Feely, J. 2002. Pharmacokinetic-pharmacody-namic drug interactions with HMG-CoA reductase inhibitors. Clin. Pharmacokinet. 41(5): 343-370. doi:10.2165/00003088-200241050-00003. PMID:12036392.
44. Yamamoto, T., Suzuki, A., and Kohno, Y. 2002. Application of microtiter plate assay to evaluate inhibitory effects of various compounds on nine cytochrome P450 isoforms and to estimate their inhibition patterns. Drug Metab. Pharmacokinet. 17(5): 437-448. doi:10.2133/dmpk.17.437. PMID:15618695.
45. Yap, Y.G., and Camm, A.J. 2003. Drug induced QT prolongation and torsades de pointes. Heart, 89(11): 1363-1372. doi:10.1136/ heart.89.11.1363. PMID:14594906.
46. Yap, K.Y., See, C.S., and Chan, A. 2010. Clinically-relevant chemotherapy interactions with complementary and alternative medicines in patients with cancer. Recent Pat. Food Nutr. Agric. 2(1): 12-55. doi:10.2174/1876142911002010012.
47. Young, T.K., Reading, J., Elias, B., and O'Neil, J.D. 2000. Type 2 diabetes mellitus in Canada's first nations: Status of an epidemic in progress. CMAJ, 163(5): 561-566. PMID:11006768.
48. Yu, C.H.Y., and Zinman, B. 2007. Type 2 diabetes and impaired glucose tolerance in aboriginal populations: a global perspective. Diabetes Res. Clin. Pract. 78(2): 159-170. doi:10.1016/j.diabres. 2007.03.022. PMID:17493702.
49. Zhao, X.J., Jones, D.R., Wang, Y.H., Grimm, S.W., and Hall, S.D. 2002. Reversible and irreversible inhibition of CYP3A enzymes by tamoxifen and metabolites. Xenobiotica, 32(10): 863-878. doi:10.1080/00498250210158230. PMID:12419016.
50. Zhou, S., Chan, E., Lim, L.Y., Boelsterli, U.A., Li, S.C., Wang, J., et al. 2004. Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4. Curr. Drug Metab. 5(5): 415-442. doi:10.2174/1389200043335450. PMID:15544435.
51. Zhou, S., Yung Chan, S., Cher Goh, B., Chan, E., Duan, W., Huang, M., and McLeod, H.L. 2005. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin. Pharmacokinet. 44(3): 279-304. doi:10.2165/00003088-200544030-00005. PMID:15762770.
52. Zou, L., Harkey, M.R., and Henderson, G.L. 2002. Effects of intrinsic fluorescence and quenching on fluorescence-based screening of natural products. Phytomedicine, 9(3): 263-267. doi:10.1078/0944-7113-00121. PMID:12046870.